In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907 | PMC |
| http://dx.doi.org/10.1177/2045894018769305 | DOI Listing |
Publication Analysis
Top Keywords
portopulmonary hypertension
8
riociguat treatment
4
treatment portopulmonary
4
hypertension subgroup
4
subgroup analysis
4
analysis patent-1/-2
4
patent-1/-2 studies
4
studies patients
4
patients portopulmonary
4
hypertension n = 13
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!